- ML-guided antibody design with wet lab iteration
- Focuses on antibody discovery depth over broad coverage
- Supports organization-wide antibody discovery programs
BigHat Biosciences
ML and wet-lab antibody design loop
SF7.1
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Bridge AI design and wet lab cyclesAntibody engineering and biotech teams
Bridge AI design and wet lab cyclesAntibody engineering and biotech teams
Best for
Antibody engineering and biotech teams
Pricing
Custom
SoftFinders Score
7.1 / 10
Overview
What is BigHat Biosciences?
BigHat Biosciences is an AI antibody design company for biotech teams, pairing machine learning with a synthesis-and-test lab to support antibody engineering.
- Research focus: It supports R&D acceleration and computational biology rather than guaranteed clinical outcomes, with downstream validation still required for candidates.
- Best-fit environment: Antibody engineering and biotech teams may benefit most when ML-guided design and wet-lab iteration align with established discovery workflows.
- Engagement model: Work typically runs through pharma partnerships rather than self-service subscriptions, making data access, validation timelines, and collaboration structure important considerations.
- Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, while engagement remains partnership and pipeline-led.
BigHat Biosciences is best assessed through a pilot that tests workflow fit, data requirements, and collaboration needs before wider commitment.
KEY FEATURES
What you get out of the box
Multi Omics
Integrates genomic and other omics data sources
Lab Integration
Connects discovery insights with wet-lab workflows
Partner Workflows
Workflows for pharma partner collaborations
Target Discovery
Identifies potential drug targets from biological data
Molecule Design
Generates and ranks small molecule candidates
Protein Modeling
Predicts and designs protein structures
USE CASES
Where teams put it to work
Bridge AI design and wet lab cycles
Identify drug targets from biology data
Accelerate molecule design cycles
Support protein engineering programs
Mine literature for research signals
Run virtual screens against targets
Editorial Take
What we like, and what to verify
- Engagement remains partnership and pipeline-led
- Drug success still depends on downstream trials
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Iktos SF 7.4
Why consider it
Generative chemistry and synthesis planning AI
Cradle SF 7.5
Why consider it
AI protein design for wet labs
Chai Discovery SF 7.3
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.7
Why consider it
Generative protein design across modalities
Causaly SF 7.6
Why consider it
Biomedical evidence and reasoning for R&D
FAQ